ALS Nexus 2025 event aiming to make disease ‘livable’ for patients
The ALS Association this summer will host the second edition of its ALS Nexus, a conference bringing together…
Articles by Margarida Maia, PhD
Qalsody halts disease progression in SOD1-ALS patients: Study
Qalsody (tofersen) halted disease progression and improved functional independence and mobility in people with amyotrophic lateral sclerosis (ALS)…
Alchemab, Lilly partner on antibody-based treatments for ALS
Alchemab Therapeutics has partnered with Eli Lilly to develop new antibody treatments for amyotrophic lateral sclerosis (ALS)…
Healthcare costs increase as ALS progresses, Biogen study finds
Due to substantial increases in the use of healthcare resources, medical costs in the U.S. for people with amyotrophic…
Neurosense finalizing protocol for Phase 3 trial of PrimeC for ALS
Neurosense Therapeutics is working on finishing touches for the protocol of a Phase 3 study testing PrimeC, an oral…
Medicare Advantage plans in US told to cover Qalsody for SOD1-ALS
The Centers for Medicare and Medicaid Services (CMS) has issued a directive requiring that Medicare Advantage plans cover Qalsody…
Study finds early-life events may be environmental risk factors for ALS
People with amyotrophic lateral sclerosis (ALS) are more likely than those without the neurodegenerative disease to have grown up…
MN-166 may slow ALS progression over year, trial data suggest
MN-166 (ibudilast), an investigational oral treatment for amyotrophic lateral sclerosis (ALS), appears to slow disease progression over up…
Utreloxastat fails to slow ALS disease progression in Phase 2 trial
Twice-daily treatment with PTC Therapeutics’ oral candidate utreloxastat failed to significantly slow disease progression in adults with amyotrophic…
Lilly to develop ALS therapies against targets ID’d with Verge tech
Eli Lilly will develop therapies against two drug targets for amyotrophic lateral sclerosis (ALS) that were identified and…